EASL Recommendations on Treatment of Hepatitis C 2018

Journal of Hepatology

Volumn 69, Issue 2, 2018, Pages 461-511

  Pawlotsky, Jean Michel ^a   Negro, Francesco ^a   Aghemo, Alessio ^a   Berenguer, Marina ^a   Dalgard, Olav ^a   Dusheiko, Geoffrey ^a   Marra, Fiona ^a   Puoti, Massimo ^a   Wedemeyer, Heiner ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BILIRUBIN; DASABUVIR; ELBASVIR; GLECAPREVIR; GLECAPREVIR PLUS PIBRENTASVIR; GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; OPIATE; PARITAPREVIR; PIBRENTASVIR; RITONAVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR; VELPATASVIR; VOXILAPREVIR;

ACUTE HEPATITIS C; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORE; CHRONIC HEPATITIS C; CLINICAL DECISION MAKING; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DISEASE SEVERITY ASSESSMENT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOLLOW UP; GENOTYPE; GRAFT RECIPIENT; HEADACHE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS SUBTYPE 1B; HEPATITIS C VIRUS SUBTYPE 3A; HEPATITIS C VIRUS SUBTYPE 3B; HUMAN; INSOMNIA; LIMIT OF QUANTITATION; LIVER DISEASE; LIVER TRANSPLANTATION; MEDICATION COMPLIANCE; MIXED INFECTION; NAUSEA; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS RESISTANCE; ACUTE DISEASE; CHRONIC DISEASE; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ACUTE DISEASE; CHRONIC DISEASE; DIAGNOSTIC SCREENING PROGRAMS; HEPATITIS C; HUMANS; PATIENT CARE MANAGEMENT; RISK ASSESSMENT; RISK FACTORS;

EID: 85045090719     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.03.026     Document Type: Article

References (305)

1. Polaris Observatory HCV Collaborators, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 161–176.
2. European Union HCV Collaborators, Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 325–336.
3. Arase, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Kawamura, Y., Akuta, N., et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 57 (2013), 964–973.
4. van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
5. Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 64 (2016), 1217–1223.
6. Kew, M.C., Interaction between hepatitis B and C viruses in hepatocellular carcinogenesis. J Viral Hepat 13 (2006), 145–149.
7. Kew, M.C., Yu, M.C., Kedda, M.A., Coppin, A., Sarkin, A., Hodkinson, J., The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 112 (1997), 184–187.
8. Nahon, P., Bourcier, V., Layese, R., Audureau, E., Cagnot, C., Marcellin, P., et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152 (2017), 142–156 e2.
9. Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J., Bell, B.P., The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006), 529–538.
10. Negro, F., Forton, D., Craxi, A., Sulkowski, M.S., Feld, J.J., Manns, M.P., Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
11. Cacoub, P., Commarmond, C., Sadoun, D., Desbois, A.C., Hepatitis C virus infection and rheumatic diseases: the impact of direct-acting antiviral agents. Rheum Dis Clin North Am 43 (2017), 123–132.
12. Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Piette, J.C., et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 42 (1999), 2204–2212.
13. Caviglia, G.P., Sciacca, C., Abate, M.L., Olivero, A., Rosso, C., Touscoz, G.A., et al. Chronic hepatitis C virus infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and B-cell non-Hodgkin lymphoma. J Gastroenterol Hepatol 30 (2015), 742–747.
14. Mahale, P., Engels, E.A., Li, R., Torres, H.A., Hwang, L.Y., Brown, E.L., et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut 67 (2018), 553–561.
15. van der Meer, A.J., Berenguer, M., Reversion of disease manifestations after HCV eradication. J Hepatol 65 (2016), S95–S108.
16. Younossi, Z.M., Hepatitis C infection: a systemic disease. Clin Liver Dis 21 (2017), 449–453.
17. Andrews, J., Guyatt, G., Oxman, A.D., Alderson, P., Dahm, P., Falck-Ytter, Y., et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66 (2013), 719–725.
18. Chevaliez, S., Pawlotsky, J.M., Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 22 (2008), 1031–1048.
19. Kamili, S., Drobeniuc, J., Araujo, A.C., Hayden, T.M., Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 55 (2012), S43–S48.
20. Takaki, A., Wiese, M., Maertens, G., Depla, E., Seifert, U., Liebetrau, A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 (2000), 578–582.
21. Terrault, N.A., Pawlotsky, J.M., McHutchison, J., Anderson, F., Krajden, M., Gordon, S., et al. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat 12 (2005), 465–472.
22. Ticehurst, J.R., Hamzeh, F.M., Thomas, D.L., Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol 45 (2007), 2426–2433.
23. Chevaliez, S., Feld, J., Cheng, K., Wedemeyer, H., Sarrazin, C., Maasoumy, B., et al. Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. Antivir Ther, 2018 in press.
24. Chevaliez, S., Soulier, A., Poiteau, L., Bouvier-Alias, M., Pawlotsky, J.M., Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol 61 (2014), 145–148.
25. Heidrich, B., Pischke, S., Helfritz, F.A., Mederacke, I., Kirschner, J., Schneider, J., et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients. J Viral Hepat 21 (2014), 769–779.
26. Freiman, J.M., Tran, T.M., Schumacher, S.G., White, L.F., Ongarello, S., Cohn, J., et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med 165 (2016), 345–355.
27. Bulteel, N., Sarathy, P.P., Forrest, E., Stanley, A.J., Innes, H., Mills, P.R., et al. Factors associated with spontaneous clearance of chronic hepatitis C virus infection. J Hepatol 65 (2016), 266–272.
28. Chhatwal, J., Wang, X., Ayer, T., Kabiri, M., Chung, R.T., Hur, C., et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 64 (2016), 1442–1450.
29. Pawlotsky, J.M., The end of the hepatitis C burden: really?. Hepatology 64 (2016), 1404–1407.
30. Chevaliez, S., Poiteau, L., Rosa, I., Soulier, A., Roudot-Thoraval, F., Laperche, S., et al. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Clin Microbiol Infect, 22, 2016, 459 e451–e456.
31. Khuroo, M.S., Khuroo, N.S., Khuroo, M.S., Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis. PLoS One, 10, 2015, e0121450.
32. Shivkumar, S., Peeling, R., Jafari, Y., Joseph, L., Pant, Pai N., Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med 157 (2012), 558–566.
33. Chapko, M.K., Dufour, D.R., Hatia, R.I., Drobeniuc, J., Ward, J.W., Teo, C.G., Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology 62 (2015), 1396–1404.
34. Poiteau, L., Soulier, A., Rosa, I., Roudot-Thoraval, F., Hezode, C., Pawlotsky, J.M., et al. Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots. J Viral Hepat 23 (2016), 399–401.
35. Soulier, A., Poiteau, L., Rosa, I., Hezode, C., Roudot-Thoraval, F., Pawlotsky, J.M., et al. Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring. J Infect Dis 213 (2016), 1087–1095.
36. Tuaillon, E., Mondain, A.M., Meroueh, F., Ottomani, L., Picot, M.C., Nagot, N., et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology 51 (2010), 752–758.
37. Grebely, J., Lamoury, F.M.J., Hajarizadeh, B., Mowat, Y., Marshall, A.D., Bajis, S., et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. Lancet Gastroenterol Hepatol 2 (2017), 514–520.
38. Martinot-Peignoux, M., Stern, C., Maylin, S., Ripault, M.P., Boyer, N., Leclere, L., et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51 (2010), 1122–1126.
39. Swain, M.G., Lai, M.Y., Shiffman, M.L., Cooksley, W.G., Zeuzem, S., Dieterich, D.T., et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139 (2010), 1593–1601.
40. Aghemo, A., Degasperi, E., De Nicola, S., Bono, P., Orlandi, A., D'Ambrosio, R., et al. Quantification of core antigen monitors efficacy of direct-acting antiviral agents in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 14 (2016), 1331–1336.
41. European Association for Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63 (2015), 237–264.
42. Afdhal, N.H., Bacon, B.R., Patel, K., Lawitz, E.J., Gordon, S.C., Nelson, D.R., et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 13 (2015), 772–779 e771–e773.
43. Chou, R., Wasson, N., Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 158 (2013), 807–820.
44. Degos, F., Perez, P., Roche, B., Mahmoudi, A., Asselineau, J., Voitot, H., et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 53 (2010), 1013–1021.
45. Herrmann, E., de Ledinghen, V., Cassinotto, C., Chu, W.C., Leung, V.Y., Ferraioli, G., et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology 67 (2018), 260–272.
46. Hu, X., Qiu, L., Liu, D., Qian, L., Acoustic Radiation Force Impulse (ARFI) elastography for noninvasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. Med Ultrason 19 (2017), 23–31.
47. Zarski, J.P., Sturm, N., Desmorat, H., Melin, P., Raabe, J.J., Bonny, C., et al. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study. Liver Int 30 (2010), 1049–1058.
48. Castera, L., Sebastiani, G., Le Bail, B., de Ledinghen, V., Couzigou, P., Alberti, A., Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 52 (2010), 191–198.
49. Castera, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005), 343–350.
50. Chevaliez, S., Bouvier-Alias, M., Brillet, R., Pawlotsky, J.M., Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One, 4, 2009, e8209.
51. Rodriguez, C., Soulier, A., Demontant, V., Poiteau, L., Mercier-Darty, M., Bouvier-Alias, M., et al. A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination. Sci Rep, 8, 2018, 4180.
52. Fourati, S., Pawlotsky, J.M., Virologic tools for HCV drug resistance testing. Viruses 7 (2015), 6346–6359.
53. Pawlotsky, J.M., Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151 (2016), 70–86.
54. European Association for the Study of the Liver, EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 66 (2017), 153–194.
55. Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
56. Manns, M., Samuel, D., Gane, E.J., Mutimer, D., McCaughan, G., Buti, M., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16 (2016), 685–697.
57. Coilly, A., Pageaux, G.P., Houssel-Debry, P., Duvoux, C., Radenne, S., De Ledinghen, V., et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs?. Hepatology, 62, 2015, 257A.
58. Belli, L.S., Berenguer, M., Cortesi, P.A., Strazzabosco, M., Rockenschaub, S.R., Martini, S., et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 65 (2016), 524–531.
59. Chhatwal, J., Samur, S., Kues, B., Ayer, T., Roberts, M.S., Kanwal, F., et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology 65 (2017), 777–788.
60. Pascasio, J.M., Vinaixa, C., Ferrer, M.T., Colmenero, J., Rubin, A., Castells, L., et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 67 (2017), 1168–1176.
61. Desnoyer, A., Pospai, D., Le, M.P., Gervais, A., Heurgue-Berlot, A., Laradi, A., et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 65 (2016), 40–47.
62. Lawitz, E., Landis, C.S., Maliakkal, B.J., Bonacini, M., Ortiz-Lasanta, G., Zhang, J., et al. Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 HCV-infected patients with severe renal impairment. Hepatology, 66, 2017, 848A.
63. Terrault, N.A., Zeuzem, S., Di Bisceglie, A.M., Lim, J.K., Pockros, P.J., Frazier, L.M., et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology 151 (2016), 1131–1140 e1135.
64. European Association for the Study of the Liver, EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55 (2011), 245–264.
65. European Association for the Study of the Liver, EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60 (2014), 392–420.
66. European Association for Study of the Liver, EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 63 (2015), 199–236.
67. Feld, J.J., Jacobson, I.M., Hezode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and velpatasvir for HCV gGenotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
68. Tsai, N., Bacon, B., Curry, M., Dieterich, D., Flamm, S., Kowdley, K., et al. Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO network. J Hepatol, 66, 2017, S726.
69. Landis, C.S., Sulkowski, M.S., Reau, N., Lutchman, G.A., Vainorius, M., Welzel, T.M., et al. Safety and efficacy of velpatasvir and sofosbuvir-based regimens for the treatment of HCV genotype 1–6: results of the HCV-TARGET study. Hepatology, 66, 2017, 587A.
70. Wyles, D., Brau, N., Kottilil, S., Daar, E.S., Ruane, P., Workowski, K., et al. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-lLabel, Phase 3 study. Clin Infect Dis 65 (2017), 6–12.
71. Jacobson, I.M., Lawitz, E., Gane, E.J., Willems, B.E., Ruane, P.J., Nahass, R.G., et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 Phase 3 randomized trials. Gastroenterology 153 (2017), 113–122.
72. Zeuzem, S., Foster, G.R., Wang, S., Asatryan, A., Gane, E., Feld, J.J., et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378 (2018), 354–369.
73. Forns, X., Lee, S.S., Valdes, J., Lens, S., Ghalib, R., Aguilar, H., et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17 (2017), 1062–1068.
74. Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
75. Afdhal, N., Reddy, K.R., Nelson, D.R., Lawitz, E., Gordon, S.C., Schiff, E., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
76. Kowdley, K.V., Gordon, S.C., Reddy, K.R., Rossaro, L., Bernstein, D.E., Lawitz, E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
77. Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W.J., et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373 (2015), 705–713.
78. Reddy, K.R., Bourliere, M., Sulkowski, M., Omata, M., Zeuzem, S., Feld, J.J., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62 (2015), 79–86.
79. Wilson, E., Davitkov, P., Kwo, P.Y., Katkakuzhy, S., Qureshi, K., Sundaram, V., et al. Real-world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in Blacks with HCV: a comparative analysis of clinical trials with real-world cohorts. Hepatology, 66, 2017, 608A.
80. Kowdley, K.V., Sundaram, V., Jeon, C., Qureshi, K., Latt, N.L., Sahota, A.K., et al. 8 weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 65 (2017), 1094–1103.
81. Buggisch, P., Vermehren, J., Mauss, S., Gunther, R., Schott, E., Pathil, A., et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 68 (2018), 663–671.
82. Kowdley, K.V., Sundaram, V., Jeon, C.Y., Qureshi, K., Latt, N.L., Sahota, A., et al. 8 weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 65 (2017), 1094–1103.
83. Zeuzem, S., Ghalib, R., Reddy, K.R., Pockros, P.J., Ben Ari, Z., Zhao, Y., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163 (2015), 1–13.
84. Rockstroh, J.K., Nelson, M., Katlama, C., Lalezari, J., Mallolas, J., Bloch, M., et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2 (2015), e319–e327.
85. Kwo, P., Gane, E.J., Peng, C.Y., Pearlman, B., Vierling, J.M., Serfaty, L., et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 152 (2017), 164–175 e164.
86. Wei, L.J., Zhdanov, K., Burnevich, E., Sheen, I.S., Heo, J., Nguyen, V.K., et al. Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a Phase III randomized multinational clinical trial. J Hepatol, 66, 2017, S529.
87. Zeuzem, S., Serfaty, L., Vierling, J., Cheng, W., George, J., Sperl, J., et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol, 2018 in press.
88. Abergel, A., Loustaud-Ratti, V., Di Martino, V., Gournay, J., Larrey, D.G., Fouchard-Hubert, I., et al. High efficacy and safety of the combination HCV regimen grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: interim results of the STREAGER study. Hepatology, 66, 2017, 1257A.
89. Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370 (2014), 1983–1992.
90. Dore, G.J., Conway, B., Luo, Y., Janczewska, E., Knysz, B., Liu, Y., et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol 64 (2016), 19–28.
91. Wyles, D., Saag, M., Viani, R.M., Lalezari, J., Adeyemi, O., Bhatti, L., et al. TURQUOISE-I Part 1b: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir. J Infect Dis 215 (2017), 599–605.
92. Welzel, T.M., Asselah, T., Dumas, E.O., Zeuzem, S., Shaw, D., Hazzan, R., et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, Phase 3b trial. Lancet Gastroenterol Hepatol 2 (2017), 494–500.
93. Andreone, P., Colombo, M.G., Enejosa, J.V., Koksal, I., Ferenci, P., Maieron, A., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147 (2014), 359–365 e351.
94. Agarwal, K., Dumas, E.O., Gaeta, G.B., Lee, S., Streinu-Cercel, A., Schott, E., et al. Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: first interim safety and efficacy results from TOPAZ-I. Hepatology, 64, 2016, 427.
95. Welzel, T.M., Isakov, V., Trinh, R., Streinu-Cercel, A., Dufour, J.F., Marinho, R.T., et al. Efficacy and safety of ombitasvir, paritaprevir/ritonavir and dasabuvir without ribavirin in patients with HCV genotype 1b with or without compensated cirrhosis: pooled analysis across 5 clinical trials. J Hepatol, 64, 2016, S824.
96. Wei, L., Hou, J., Luo, Y., Heo, J., Chu, C.J., Duan, Z.P., et al. ONYX-I: safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir in Asian adults with genotype 1b chronic hepatitis C virus (HCV) infection. A randomized, double-blind, placebo-controlled study. Hepatology, 64, 2016, 432A.
97. Feld, J.J., Moreno, C., Trinh, R., Tam, E., Bourgeois, S., Horsmans, Y., et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 64 (2016), 301–307.
98. Foster, G.R., Afdhal, N., Roberts, S.K., Brau, N., Gane, E.J., Pianko, S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
99. Kwo, P.Y., Poordad, F., Asatryan, A., Wang, S., Wyles, D.L., Hassanein, T., et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 67 (2017), 263–271.
100. Toyoda, H., Chayama, K., Suzuki, F., Sato, K., Atarashi, T., Watanabe, T., et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology, 2018 in press.
101. Rockstroh, J., Lacombe, K., Viani, R.M., Orkin, C., Wyles, D., Luetkemeyer, A., et al. Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study. Clin Infect Dis, 2018 in press.
102. Foster, G.R., Gane, E., Asatryam, A., Asselah, T., Ruane, P.J., Pol, S., et al. ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis. J Hepatol, 66, 2017, S33.
103. Flamm, S.L., Wyles, D.L., Wang, S., Mutimer, D.J., Rockstroh, J.K., Horsmans, Y.J., et al. Efficacy and safety of glecaprevir/pibrentasvir for 8 or 12 weeks in treatment-naïve patients with chronic HCV genotype 3: an integrated Phase 2/3 analysis. Hepatology, 66, 2017, 35A.
104. Wyles, D., Poordad, F., Wang, S., Alric, L., Felizarta, F., Kwo, P.Y., et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized Phase 3 clinical trial. Hepatology, 2018 in press.
105. Krishnan, P., Schnell, G., Tripathi, R., Ng, T., Reisch, T., Beyer, J., et al. Pooled resistance analysis in HCV genotype 1-6-infected patients treated with glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Hepatol, 66, 2017, S500.
106. Asselah, T., Kowdley, K.V., Zadeikis, N., Wang, S., Hassanein, T., Horsmans, Y., et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 16 (2018), 417–426.
107. Kohli, A., Kapoor, R., Sims, Z., Nelson, A., Sidharthan, S., Lam, B., et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label Phase 2a cohort study. Lancet Infect Dis 15 (2015), 1049–1054.
108. Abergel, A., Metivier, S., Samuel, D., Jiang, D., Kersey, K., Pang, P.S., et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 64 (2016), 1049–1056.
109. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 165 (2016), 625–634.
110. Abergel, A., Asselah, T., Metivier, S., Kersey, K., Jiang, D., Mo, H., et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 16 (2016), 459–464.
111. Lim, S.G., Mohamed, R., Le, P., Tee, H.P., McNabb, B.L., Lu, S., et al. Safety and efficacy of sofosbuvir/velpatasvir in a genotype 1–6 HCV-infected population from Singapore, Malaysia, Thailand, and Vietnam: results from a Phase 3 clinical trial. Hepatology, 66, 2017, 586A.
112. Gane, E.J., Hyland, R.H., An, D., Svarovskaia, E., Pang, P.S., Brainard, D., et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149 (2015), 1454–1461 e1451.
113. Freeman, J.A., Hill, A., The use of generic medications for hepatitis C. Liver Int 36 (2016), 929–932.
114. Garcia-Retortillo, M., Forns, X., Feliu, A., Moitinho, E., Costa, J., Navasa, M., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35 (2002), 680–687.
115. Gane, E., Pilmore, H., Management of chronic viral hepatitis before and after renal transplantation. Transplantation 74 (2002), 427–437.
116. Wedemeyer, H., Craxi, A., Zuckerman, E., Dieterich, D., Flisiak, R., Roberts, S.K., et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat 24 (2017), 936–943.
117. Foster, G.R., Irving, W.L., Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
118. Cheung, M.C.M., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (2016), 741–747.
119. Charlton, M.R., Cheung, M.C., Manns, M.P., Sajed, N., Troke, P., Spellman, J.G., et al. Ledipasvir/sofosbuvir + ribavirin (LDV/SOF + RBV) for 12 weeks in decompensated HCV genotype 1 patients: SOLAR-1 and -2 studies compared to a real-world dataset. Hepatology 64 (2016), 489A–490A.
120. Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
121. Belli, L.S., Berenguer, M., Cortesi, P.A., Facchetti, R., Strazzabosco, M., Perricone, G., et al. Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study. J Hepatol, 66, 2017, S39.
122. Cortesi, P.A., Belli, L.S., Facchetti, R., Mazzarelli, C., Perricone, G., De Nicola, S., et al. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: cost-effectiveness analysis of new opportunities. J Viral Hepat, 2018 in press.
123. Beste, L.A., Green, P.K., Berry, K., Kogut, M.J., Allison, S.K., Ioannou, G.N., Reply to: “Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything” and “More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations”. J Hepatol 68 (2018), 219–220.
124. Mazzarelli, C., Cannon, M.D., Belli, L.S., Agarwal, K., Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything. J Hepatol 68 (2018), 217–218.
125. Beste, L.A., Green, P.K., Berry, K., Kogut, M.J., Allison, S.K., Ioannou, G.N., Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 67 (2017), 32–39.
126. Forman, L.M., Lewis, J.D., Berlin, J.A., Feldman, H.I., Lucey, M.R., The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002), 889–896.
127. Prieto, M., Berenguer, M., Rayon, J.M., Cordoba, J., Arguello, L., Carrasco, D., et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29 (1999), 250–256.
128. Berenguer, M., Ferrell, L., Watson, J., Prieto, M., Kim, M., Rayon, M., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32 (2000), 673–684.
129. Samuel, D., Forns, X., Berenguer, M., Trautwein, C., Burroughs, A., Rizzetto, M., et al. Report of the Monothematic EASL Conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J Hepatol 45 (2006), 127–143.
130. Berenguer, M., Palau, A., Aguilera, V., Rayon, J.M., Juan, F.S., Prieto, M., Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 8 (2008), 679–687.
131. Picciotto, F.P., Tritto, G., Lanza, A.G., Addario, L., De Luca, M., Di Costanzo, G.G., et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 46 (2007), 459–465.
132. Blasco, A., Forns, X., Carrion, J.A., Garcia-Pagan, J.C., Gilabert, R., Rimola, A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43 (2006), 492–499.
133. Neumann, U.P., Berg, T., Bahra, M., Seehofer, D., Langrehr, J.M., Neuhaus, R., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41 (2004), 830–836.
134. Agarwal, K., Castells, L., Mullhaupt, B., Rosenberg, W.M., McNabb, B.L., Arterburn, S., et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol, 66, 2017, 571A.
135. Reau, N., Kwo, P.Y., Rhee, S., Brown, R.S., Agarwal, K., Angus, P., et al. MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection. J Hepatol, 66, 2017, S90.
136. Flamm, S.L., Everson, G.T., Charlton, M., Denning, J.M., Arterburn, S., Brandt-Sarif, T., et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology, 60, 2014, 320A.
137. Poordad, F., Schiff, E.R., Vierling, J.M., Landis, C., Fontana, R.J., Yang, R., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
138. Fernandez-Carrillo, C., Lens, S., Llop, E., Pascasio, J.M., Crespo, J., Arenas, J., et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the HEPA-C registry. Hepatology 65 (2017), 1810–1822.
139. Di Maira, T., Torregrosa, A., Navarro, V., Sanchez, D., Fornes, V., Berenguer, M., Liver volume as a predictor of functional improvement post-DAA treatment. Transplantation 102 (2018), 74–81.
140. Moon, C., Jung, K.S., Kim do, Y., Baatarkhuu, O., Park, J.Y., Kim, B.K., et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 60 (2015), 573–581.
141. Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M., Falck-Ytter, Y., Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158 (2013), 329–337.
142. Muir, A.J., Buti, M., Nahass, R., Agarwal, K., Gane, E.J., Strasser, S.I., et al. Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. Hepatology, 64, 2016, 437A.
143. Li, D.K., Ren, Y., Fierer, D.S., Rutledge, S., Shaikh, O.S., Lo Re, V., et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology, 2018 in press.
144. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
145. Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
146. Camma, C., Cabibbo, G., Craxi, A., Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. J Hepatol 65 (2016), 861–862.
147. Ravi, S., Kodali, S., Simpson, H., Alkurdi, B., McGuire, B.M., Singal, A., Unusually high HCC rates among patients with HCV cirrhosis after treatment with direct acting antivirals. Hepatology, 64, 2016, 663A.
148. Cardoso, H., Vale, A.M., Rodrigues, S., Goncalves, R., Albuquerque, A., Pereira, P., et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 65 (2016), 1070–1071.
149. Yang, J.D., Aqel, B.A., Pungpapong, S., Gores, G.J., Roberts, L.R., Leise, M.D., Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 65 (2016), 859–860.
150. Kozbial, K., Moser, S., Schwarzer, R., Laferl, H., Al-Zoairy, R., Stauber, R., et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 65 (2016), 856–858.
151. Mettke, F., Schlevogt, B., Deterding, K., Wranke, A., Smith, A., Port, K., et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther 47 (2018), 516–525.
152. Waziry, R., Hajarizadeh, B., Grebely, J., Amin, J., Law, M., Danta, M., et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 67 (2017), 1204–1212.
153. Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 45 (2017), 160–168.
154. ANRS Collaborative Study Group on Hepatocellular Carcinoma, Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 65 (2016), 734–740.
155. Minami, T., Tateishi, R., Nakagomi, R., Fujiwara, N., Sato, M., Enooku, K., et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol 65 (2016), 1272–1273.
156. Torres, H.A., Vauthey, J.N., Economides, M.P., Mahale, P., Kaseb, A., Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. J Hepatol 65 (2016), 862–864.
157. Zavaglia, C., Okolicsanyi, S., Cesarini, L., Mazzarelli, C., Pontecorvi, V., Ciaccio, A., et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?. J Hepatol 66 (2017), 236–237.
158. Yasui, Y., Kurosaki, M., Wang, W., Okada, M., Kubota, Y., Goto, T., et al. Direct acting antivirals did not increase early recurrences after curative treatment of HCV-related hepatocellular carcinoma in comparison with IFN-based treatment. J Hepatol, 66, 2017, S748.
159. Innes, H., Barclay, S.T., Hayes, P.C., Fraser, A., Dillon, J.F., Stanley, A., et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen. J Hepatol 68 (2018), 646–654.
160. Cabibbo, G., Petta, S., Calvaruso, V., Cacciola, I., Cannavo, M.R., Madonia, S., et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 46 (2017), 688–695.
161. Reddy, K.R., Bourliere, M., Agarwal, K., Lawitz, E., Osinusi, A., Kersey, K., et al. Sustained viral response following treatment with direct-acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma. J Hepatol, 66, 2017, S491.
162. Telep, L.E., Muramoto, D., Osinusi, A., Brainard, D.M., Reddy, K.R., Singer, A.W., et al. No increased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct-acting antiviral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data. J Hepatol, 66, 2017, S533.
163. Huang, A.C., Mehta, N., Dodge, J.L., Yao, F.Y., Terrault, N.A., Direct-acting antivirals for hepatitis C do not increase the risk of hepatocellular carcinoma recurrence after locoregional therapy or liver transplant wait list dropout. Hepatology, 2018 in press.
164. Virlogeux, V., Pradat, P., Hartig-Lavie, K., Bailly, F., Maynard, M., Ouziel, G., et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int 37 (2017), 1122–1127.
165. Potthoff, A., Berg, T., Wedemeyer, H., Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-α2b and ribavirin. Scand J Gastroenterol 44 (2009), 1487–1490.
166. Wang, C., Ji, D., Chen, J., Shao, Q., Li, B., Liu, J., et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 15 (2017), 132–136.
167. Liu, C.J., Chuang, W.L., Sheen, I.S., Wang, H.Y., Chen, C.Y., Tseng, K.C., et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology 154 (2018), 989–997.
168. Saadoun, D., Thibault, V., Si Ahmed, S.N., Alric, L., Mallet, M., Guillaud, C., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 75 (2016), 1777–1782.
169. Sise, M.E., Bloom, A.K., Wisocky, J., Lin, M.V., Gustafson, J.L., Lundquist, A.L., et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63 (2016), 408–417.
170. Bonacci, M., Lens, S., Londono, M.C., Marino, Z., Cid, M.C., Ramos-Casals, M., et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol 15 (2017), 575–583 e571.
171. Comarmond, C., Garrido, M., Pol, S., Desbois, A.C., Costopoulos, M., Le Garff-Tavernier, M., et al. Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis. Gastroenterology 152 (2017), 2052–2062 e2052.
172. Emery, J.S., Kuczynski, M., La, D., Almarzooqi, S., Kowgier, M., Shah, H., et al. Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol 112 (2017), 1298–1308.
173. Gragnani, L., Piluso, A., Urraro, T., Fabbrizzi, A., Fognani, E., Petraccia, L., et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets 18 (2017), 772–785.
174. Saadoun, D., Pol, S., Ferfar, Y., Alric, L., Hezode, C., Si Ahmed, S.N., et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology 153 (2017), 49–52 e45.
175. Lim, L.Y., La, D., Cserti-Gazdewich, C.M., Shah, H., Lymphoma remission by interferon-free HCV eradication without chemotherapy. ACG Case Rep J 3 (2015), 69–70.
176. Sultanik, P., Klotz, C., Brault, P., Pol, S., Mallet, V., Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 125 (2015), 2446–2447.
177. Arcaini, L., Besson, C., Frigeni, M., Fontaine, H., Goldaniga, M., Casato, M., et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 128 (2016), 2527–2532.
178. Persico, M., Aglitti, A., Caruso, R., De Renzo, A., Selleri, C., Califano, C., et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. Hepatology 67 (2018), 48–55.
179. Lai, T.S., Lee, M.H., Yang, H.I., You, S.L., Lu, S.N., Wang, L.Y., et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology 66 (2017), 784–793.
180. Cox-North, P., Hawkins, K.L., Rossiter, S.T., Hawley, M.N., Bhattacharya, R., Landis, C.S., Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun 1 (2017), 248–255.
181. Saxena, V., Koraishy, F.M., Sise, M.E., Lim, J.K., Schmidt, M., Chung, R.T., et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36 (2016), 807–816.
182. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf.
183. Pockros, P.J., Reddy, K.R., Mantry, P.S., Cohen, E., Bennett, M., Sulkowski, M.S., et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150 (2016), 1590–1598.
184. Roth, D., Nelson, D.R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H. Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386 (2015), 1537–1545.
185. Bruchfeld, A., Roth, D., Martin, P., Nelson, D.R., Pol, S., Londono, M.C., et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2 (2017), 585–594.
186. Kramer, J.R., Puenpatom, A., Erickson, K., Cao, Y., Smith, D.L., El-Serag, H.B., et al. Effectiveness of elbasvir/grazoprevir in patients with chronic hepatitis C and chronic kidney disease: results from the Veterans Affairs system. Hepatology, 66, 2017, 597A.
187. Gane, E., Lawitz, E., Pugatch, D., Papatheodoridis, G., Brau, N., Brown, A., et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377 (2017), 1448–1455.
188. Pol, S., Pockros, P., Pugatch, D., Brau, N., Landis, C., Elkhashab, M., et al. Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 and chronic kidney disease: an integrated analysis. J Hepatol, 66, 2017, S738.
189. Beinhardt, S., Al Zoairy, R., Ferenci, P., Kozbial, K., Freissmuth, C., Stern, R., et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int 29 (2016), 999–1007.
190. Kamar, N., Marion, O., Rostaing, L., Cointault, O., Ribes, D., Lavayssiere, L., et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 16 (2016), 1474–1479.
191. Lin, M.V., Sise, M.E., Pavlakis, M., Amundsen, B.M., Chute, D., Rutherford, A.E., et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection. PLoS One, 11, 2016, e0158431.
192. Colombo, M., Aghemo, A., Liu, H., Zhang, J., Dvory-Sobol, H., Hyland, R., et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med 166 (2017), 109–117.
193. Saxena, V., Khungar, V., Verna, E.C., Levitsky, J., Brown, R.S. Jr, Hassan, M.A., et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology 66 (2017), 1090–1101.
194. Goldberg, D.S., Abt, P.L., Reese, P.P., Transplanting HCV-infected kidneys into uninfected recipients. N Engl J Med, 377, 2017, 1105.
195. Scott, D.R., Wong, J.K., Spicer, T.S., Dent, H., Mensah, F.K., McDonald, S., et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 90 (2010), 1165–1171.
196. van Wagner, L.B., Baker, T., Ahya, S.N., Norvell, J.P., Wang, E., Levitsky, J., Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol 51 (2009), 874–880.
197. Eisenberger, U., Guberina, H., Willuweit, K., Bienholz, A., Kribben, A., Gerken, G., et al. Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients. Transplantation 101 (2017), 980–986.
198. Fernandez, I., Munoz-Gomez, R., Pascasio, J.M., Baliellas, C., Polanco, N., Esforzado, N., et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol 66 (2017), 718–723.
199. Lubetzky, M., Chun, S., Joelson, A., Coco, M., Kamal, L., Ajaimy, M., et al. Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents. Transplantation 101 (2017), 1704–1710.
200. Morales, A.L., Liriano-Ward, L., Tierney, A., Sang, M., Lalos, A., Hassan, M., et al. Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. Clin Transplant, 31, 2017, e12941.
201. Liu, C.H., Chen, Y.S., Wang, S.S., Liu, C.J., Su, T.H., Yang, H.C., et al. Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection. Clin Infect Dis 66 (2018), 289–292.
202. D'Ambrosio, R., Aghemo, A., Rossetti, V., Carrinola, R., Colombo, M., Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. Liver Int 36 (2016), 1585–1589.
203. Bari, K., Luckett, K., Kaiser, T., Diwan, T., Cuffy, M., Schoech, M., et al. Hepatitis C transmission from seropositive, non-viremic donors to non-hepatitis C liver transplant recipients. Hepatology, 2018 in press.
204. Coilly, A., Samuel, D., Pros and Cons: Usage of organs from donors infected with hepatitis C virus. Revision in the direct-acting antiviral era. J Hepatol 64 (2016), 226–231.
205. Bowring, M.G., Kucirka, L.M., Massie, A.B., Luo, X., Cameron, A., Sulkowski, M., et al. Changes in utilization and discard of hepatitis C-infected donor livers in the recent era. Am J Transplant 17 (2017), 519–527.
206. Zibbell, J.E., Asher, A.K., Patel, R.C., Kupronis, B., Iqbal, K., Ward, J.W., et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health 108 (2018), 175–181.
207. Larney, S., Grebely, J., Hickman, M., De Angelis, D., Dore, G.J., Degenhardt, L., Defining populations and injecting parameters among people who inject drugs: implications for the assessment of hepatitis C treatment programs. Int J Drug Policy 26 (2015), 950–957.
208. Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L.T., Hickman, M., et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis 16 (2016), 1385–1398.
209. Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 5 (2017), e1192–e1207.
210. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378 (2011), 571–583.
211. Hagan, H., Pouget, E.R., Des Jarlais, D.C., Lelutiu-Weinberger, C., Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 168 (2008), 1099–1109.
212. Aspinall, E.J., Weir, A., Sacks-Davis, R., Spelman, T., Grebely, J., Higgs, P., et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. Int J Drug Policy 25 (2014), 179–182.
213. Bruneau, J., Zang, G., Abrahamowicz, M., Jutras-Aswad, D., Daniel, M., Roy, E., Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. Clin Infect Dis 58 (2014), 755–761.
214. de Vos, A.S., Prins, M., Kretzschmar, M.E., Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?. Addiction 110 (2015), 975–983.
215. Hellard, M., Rolls, D.A., Sacks-Davis, R., Robins, G., Pattison, P., Higgs, P., et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 60 (2014), 1861–1870.
216. Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M., Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 54 (2011), 1137–1144.
217. Martin, N.K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S.J., Lima, V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
218. Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55 (2012), 49–57.
219. van der Meer, A.J., Wedemeyer, H., Feld, J.J., Dufour, J.F., Zeuzem, S., Hansen, B.E., et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312 (2014), 1927–1928.
220. Page, K., Morris, M.D., Hahn, J.A., Maher, L., Prins, M., Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 57 (2013), S32–S38.
221. Wiessing, L., Ferri, M., Grady, B., Kantzanou, M., Sperle, I., Cullen, K.J., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One, 9, 2014, e103345.
222. Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev, 9, 2017, CD012021.
223. Larney, S., Peacock, A., Leung, J., Colledge, S., Hickman, M., Vickerman, P., et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health 5 (2017), e1208–e1220.
224. Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384 (2014), 1953–1997.
225. Alavi, M., Raffa, J.D., Deans, G.D., Lai, C., Krajden, M., Dore, G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int 34 (2014), 1198–1206.
226. Midgard, H., Bramness, J.G., Skurtveit, S., Haukeland, J.W., Dalgard, O., Hepatitis C treatment uptake among patients who have received opioid substitution treatment: a population-based study. PLoS One, 11, 2016, e0166451.
227. Grebely, J., Dalgard, O., Conway, B., Cunningham, E.B., Bruggmann, P., Hajarizadeh, B., et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol, 2018 in press.
228. Grebely, J., Dore, G.J., Zeuzem, S., Aspinall, R.J., Fox, R., Han, L., et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution tTherapy: analysis of Phase 3 ASTRAL trials. Clin Infect Dis 63 (2016), 1479–1481.
229. Grebely, J., Jacobson, I., Kayali, Z., Verna, E.C., Shiffmann, M.L., Hyland, R.H., et al. SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy. J Hepatol, 66, 2017, S513.
230. Grebely, J., Mauss, S., Brown, A., Bronowicki, J.P., Puoti, M., Wyles, D., et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of Phase 3 ION trials. Clin Infect Dis 63 (2016), 1405–1411.
231. Grebely, J., Puoti, M., Wedemeyer, H., Cooper, C., Sulkowski, M.S., Foster, G., et al. Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials. J Hepatol, 66, 2017, S514.
232. Lalezari, J., Sullivan, J.G., Varunok, P., Galen, E., Kowdley, K.V., Rustgi, V., et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 63 (2015), 364–369.
233. Conway B, Grebely J, Fraser C, Moriggia A, Cunningham EB, Gane E, et al. Paritaprevir/ritonavir/ombitasvir, dasabuvir + ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving OST: D3FEAT study. INHSU 2017 – The International Network on Hepatitis in Substance Users, Jersey City, September 6–8, 2017.
234. Boglione, L., Pinna, S.M., De Nicolo, A., Cusato, J., Cariti, G., Di Perri, G., et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study. J Viral Hepat 24 (2017), 850–857.
235. Grebely, J., Dalgard, O., Conway, B., Cunningham, E.B., Bruggman, P., Hajarizadeh, B., et al. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study. J Hepatol, 66, 2017, S513.
236. Mason, K., Dodd, Z., Guyton, M., Tookey, P., Lettner, B., Matelski, J., et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto. Canada. Int J Drug Policy 47 (2017), 202–208.
237. Morris, L., Smirnov, A., Kvassay, A., Leslie, E., Kavanagh, R., Alexander, N., et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland Injectors’ Health Network. Int J Drug Policy 47 (2017), 216–220.
238. Norton, B.L., Fleming, J., Bachhuber, M.A., Steinman, M., DeLuca, J., Cunningham, C.O., et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 47 (2017), 196–201.
239. Read, P., Lothian, R., Chronister, K., Gilliver, R., Kearley, J., Dore, G.J., et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy 47 (2017), 209–215.
240. Litwin, A.H., Agyemang, L., Akiyama, M.J., Norton, B.L., Heo, M., Ning, Y., et al. The PREVAIL study: intensive models of HCV care for people who inject drugs. J Hepatol, 66, 2017, S72.
241. Bouscaillou, J., Kikvidze, T., Butsashvili, M., Labartkava, K., Inaridze, I., Etienne, A., et al. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle-income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia. J Hepatol, 66, 2017, S409.
242. Conway, B., Raycraft, T., Alimohammadi, A., Bhutani, Y., Kiani, G., Hakobyan, S., Efficacy of all-oral HCV therapy in people who inject drugs (PWID). Hepatology, 64, 2016, 990A.
243. Sulkowski, M., Ward, K., Falade-Nwulia, O., Moon, J., Sutcliffe, C., Brinkley, S., et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS Study. J Hepatol, 66, 2017, S719.
244. Christensen, S., Buggisch, P., Mauss, S., Boker, K.H.W., Schott, E., Klinker, H., et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. Addiction, 2018 in press.
245. Bruggmann, P., Litwin, A.H., Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 57 (2013), S56–S61.
246. Aspinall, E.J., Corson, S., Doyle, J.S., Grebely, J., Hutchinson, S.J., Dore, G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 57 (2013), S80–S89.
247. Cunningham, E.B., Applegate, T.L., Lloyd, A.R., Dore, G.J., Grebely, J., Mixed HCV infection and reinfection in people who inject drugs: impact on therapy. Nat Rev Gastroenterol Hepatol 12 (2015), 218–230.
248. Grady, B.P., Schinkel, J., Thomas, X.V., Dalgard, O., Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 57 (2013), S105–S110.
249. Midgard, H., Bjoro, B., Maeland, A., Konopski, Z., Kileng, H., Damas, J.K., et al. Hepatitis C reinfection after sustained virological response. J Hepatol 64 (2016), 1020–1026.
250. Midgard, H., Weir, A., Palmateer, N., Lo Re, V. 3rd, Pineda, J.A., Macias, J., et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol 65 (2016), S33–S45.
251. Simmons, B., Saleem, J., Hill, A., Riley, R.D., Cooke, G.S., Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62 (2016), 683–694.
252. Dore, G.J., Grebely, J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., et al. Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): CO-STAR Part B. Hepatology, 66, 2017, 112A.
253. Fraser, H., Zibbell, J., Hoerger, T., Hariri, S., Vellozzi, C., Martin, N.K., et al. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Addiction 113 (2018), 173–182.
254. Martin, N.K., Hickman, M., Hutchinson, S.J., Goldberg, D.J., Vickerman, P., Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 57 (2013), S39–S45.
255. Lai, M.E., Origa, R., Danjou, F., Leoni, G.B., Vacquer, S., Anni, F., et al. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol 90 (2013), 501–507.
256. Hezode, C., Colombo, M., Bourliere, M., Spengler, U., Ben-Ari, Z., Strasser, S.I., et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a Phase III study. Hepatology 66 (2017), 736–745.
257. Origa, R., Ponti, M.L., Filosa, A., Galeota Lanza, A., Piga, A., Saracco, G.M., et al. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol 92 (2017), 1349–1355.
258. Gonzalez-Peralta, R.P., Langham, M.R. Jr, Andres, J.M., Mohan, P., Colombani, P.M., Alford, M.K., et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 48 (2009), 630–635.
259. Mohan, P., Barton, B.A., Narkewicz, M.R., Molleston, J.P., Gonzalez-Peralta, R.P., Rosenthal, P., et al. Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study. Hepatology 58 (2013), 1580–1586.
260. Castellino, S., Lensing, S., Riely, C., Rai, S.N., Davila, R., Hayden, R.T., et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. Blood 103 (2004), 2460–2466.
261. Balistreri, W.F., Murray, K.F., Rosenthal, P., Bansal, S., Lin, C.H., Kersey, K., et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology 66 (2017), 371–378.
262. Wirth, S., Rosenthal, P., Gonzalez-Peralta, R.P., Jonas, M.M., Balistreri, W.F., Lin, C.H., et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 66 (2017), 1102–1110.
263. Vermehren, J., Susser, S., Dietz, J., von Hahn, T., Petersen, J., Hinrichsen, H., et al. Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database. J Hepatol, 64, 2016, S188.
264. Dietz, J., Susser, S., Vermehren, J., Peiffer, K.H., Grammatikos, G., Berger, A., et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology 154 (2018), 976–988.
265. Bourliere, M., Gordon, S.C., Flamm, S.L., Cooper, C.L., Ramji, A., Tong, M., et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376 (2017), 2134–2146.
266. Poordad, F., Pol, S., Asatryan, A., Buti, M., Shaw, D., Hezode, C., et al. Glecaprevir/pibrentasvir in patients with HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Hepatology 67 (2018), 1253–1260.
267. http://www.natap.org/2018/CROI/croi_57.htm.
268. Bethea, E.D., Chen, Q., Hur, C., Chung, R.T., Chhatwal, J., Should we treat acute hepatitis C?. A decision and cost-effectiveness analysis. Hepatology 67 (2018), 837–848.
269. Martinello, M., Gane, E., Hellard, M., Sasadeusz, J., Shaw, D., Petoumenos, K., et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study. Hepatology 64 (2016), 1911–1921.
270. Naggie, S., Marks, K.M., Hughes, M., Fierer, D.S., Macbrayne, C., Kim, A., et al. Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1-infected individuals: SWIFT-C. Clin Infect Dis 64 (2017), 1035–1042.
271. Basu, P.P., Shah, N.J., Aloysius, M.M., Brown, R. Jr, Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir for acute hepatitis C: a RCT: SLAM C study. Hepatol Int 10 (2016), S14–S15.
272. Rockstroh, J.K., Bhagani, S., Hyland, R.H., Yun, C., Dvory-Sobol, H., Zheng, W., et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol 2 (2017), 347–353.
273. Deterding, K., Spinner, C.D., Schott, E., Welzel, T.M., Gerken, G., Klinker, H., et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, Phase 2 study. Lancet Infect Dis 17 (2017), 215–222.
274. Martinello, M., Bhagani, S., Gane, E.J., Orkin, C., Cooke, G.S., Kulasegaram, R., et al. Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: the TARGET3D Study. Hepatology, 66, 2017, 574A.
275. Chevaliez, S., Bouvier-Alias, M., Brillet, R., Pawlotsky, J.M., Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46 (2007), 22–31.
276. Sarrazin, C., Shiffman, M.L., Hadziyannis, S.J., Lin, A., Colucci, G., Ishida, H., et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 52 (2010), 832–838.
277. Vermehren, J., Kau, A., Gartner, B.C., Gobel, R., Zeuzem, S., Sarrazin, C., Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 46 (2008), 3880–3891.
278. Dufour, J.F., Zuckerman, E., Zadeikis, N., Hezode, C., Paik, S.W., Andreone, P., et al. Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection: an integrated analysis. J Hepatol, 66, 2017, S515.
279. Renard, S., Borentain, P., Salaun, E., Benhaourech, S., Maille, B., Darque, A., et al. Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir. Chest 149 (2016), e69–e73.
280. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L. Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002), 975–982.
281. Hadziyannis, S.J., Sette, H. Jr, Morgan, T.R., Balan, V., Diago, M., Marcellin, P., et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004), 346–355.
282. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001), 958–965.
283. Fried, M.W., Side effects of therapy of hepatitis C and their management. Hepatology 36 (2002), S237–S244.
284. Shiffman, M.L., Salvatore, J., Hubbard, S., Price, A., Sterling, R.K., Stravitz, R.T., et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 46 (2007), 371–379.
285. Soza, A., Everhart, J.E., Ghany, M.G., Doo, E., Heller, T., Promrat, K., et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 36 (2002), 1273–1279.
286. Afdhal, N.H., Dieterich, D.T., Pockros, P.J., Schiff, E.R., Shiffman, M.L., Sulkowski, M.S., et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126 (2004), 1302–1311.
287. Pockros, P.J., Shiffman, M.L., Schiff, E.R., Sulkowski, M.S., Younossi, Z., Dieterich, D.T., et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 40 (2004), 1450–1458.
288. Sulkowski, M.S., Poordad, F., Manns, M.P., Bronowicki, J.P., Rajender Reddy, K., Harrison, S.A., et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 57 (2013), 974–984.
289. Marra, F., Datta, S., Priest, M., Heydtmann, M., Fox, R., Barclay, S.T., Introduction of directly observed community pharmacy dispensing of direct-acting antivirals achieves high sustained viral response rates in a difficult to treat cohort. J Hepatol, 64, 2016, S766.
290. Boyle, A., Marra, F., Fox, R., Morris, J., Fleming, C., Reilly, E., et al. Partial directly observed therapy with ombitasvir/paritaprevir-based regimens allows for successful treatment of patients on daily supervised methadone. J Hepatol, 66, 2017, S282.
291. Alavian, S.M., Aalaei-Andabili, S.H., Education by a nurse increases the adherence to therapy in chronic hepatitis C patients. Clin Gastroenterol Hepatol, 10, 2012, 203.
292. Rodis, J.L., Kibbe, P., Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs 33 (2010), 368–373.
293. Alexander, J.A., Hearld, L.R., Mittler, J.N., Harvey, J., Patient-physician role relationships and patient activation among individuals with chronic illness. Health Serv Res 47 (2012), 1201–1223.
294. Tsui, J.I., Williams, E.C., Green, P.K., Berry, K., Su, F., Ioannou, G.N., Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend 169 (2016), 101–109.
295. Anand, B.S., Currie, S., Dieperink, E., Bini, E.J., Shen, H., Ho, S.B., et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 130 (2006), 1607–1616.
296. Bruggmann, P., Dampz, M., Gerlach, T., Kravecz, L., Falcato, L., Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend 110 (2010), 167–171.
297. Le Lan, C., Guillygomarc'h, A., Danielou, H., Le Dreau, G., Laine, F., Vedeilhie, C., et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol 56 (2012), 334–340.
298. Siu, L., Foont, J., Wands, J.R., Hepatitis C virus and alcohol. Semin Liver Dis 29 (2009), 188–199.
299. Bang, C.S., Song, I.H., Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol, 17, 2017, 46.
300. Backmund, M., Meyer, K., Edlin, B.R., Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 39 (2004), 1540–1543.
301. Currie, S.L., Ryan, J.C., Tracy, D., Wright, T.L., George, S., McQuaid, R., et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 93 (2008), 148–154.
302. Dalgard, O., Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 40 (2005), S336–S338.
303. Grebely, J., Knight, E., Ngai, T., Genoway, K.A., Raffa, J.D., Storms, M., et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 25 (2010), 1281–1284.
304. Grebely, J., Pham, S.T., Matthews, G.V., Petoumenos, K., Bull, R.A., Yeung, B., et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 55 (2012), 1058–1069.
305. Martin, T.C., Ingiliz, P., Rodger, A., Stellbrink, H.J., Mauss, S., Boesecke, C., et al. HCV reinfection incidence and outcomes among HIV-infected MSM in Western Europe. J Hepatol, 64, 2016, S138.